A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced Adenocarcinoma of the stomach and Gastroesophageal junction Academic Article uri icon

Overview

MeSH Major

  • Pancreatic Neoplasms
  • Practice Guidelines as Topic

abstract

  • The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry. This highlights the importance of correctly selecting biomarkers for targeted therapies. A multivariate analysis suggested that MET positivity may still be prognostic for worse median overall survival in gastric cancer; therefore, it is important to continue investigation into the optimal approach to inhibit MET signaling in gastric cancer.

publication date

  • September 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5016069

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2016-0038

PubMed ID

  • 27401892

Additional Document Info

start page

  • 1085

end page

  • 90

volume

  • 21

number

  • 9